Mentioned in ?
References in periodicals archive ?
The Phase II clinical trial, also underway at the NCI, is testing use of the Delcath System for the organ-specific delivery of the chemotherapeutic agent melphalan in patients with specific tumors in the liver, including primary liver cancer, metastatic neuroendocrine tumors, adenocarcinomas in the liver, and metastatic melanoma in the liver of patients who previously received isolated hepatic perfusion, but whose cancer has since returned.
Delcath Granted Japanese Patent for Delcath System
The Phase II clinical trial, also resuming enrollment at the NCI, is testing use of the Delcath System for the organ-specific delivery of the chemotherapeutic agent melphalan in patients with specific tumors in the liver, including primary liver cancer, metastatic neuroendocrine tumors, adenocarcinomas in the liver, and metastatic melanoma in the liver of patients who previously received isolated hepatic perfusion, but whose cancer has since returned.
Delcath Resumes Enrollment in Phase III and Phase II Trials
New Arm to Treat Relapsed Melanoma Patients Previously Shown to Respond to Isolated Hepatic Perfusion
Delcath Expands Phase II Multi-Histology Clinical Trial

Medical browser ?
Full browser ?